DiaMedica is a clinical-stage biopharmaceutical company developing therapies for severe ischemic diseases, primarily focusing on its lead product DM199 (Rinvecalinase Alfa), a recombinant form of human tissue kallikrein-1 designed to enhance blood flow and tissue perfusion. The company is advancing DM199 through clinical trials for two main indications: preeclampsia and fetal growth restriction in pregnant women, and acute ischemic stroke in stroke patients—a large market where most patients lack effective treatment options within the narrow therapeutic window of approved thrombolytics. DiaMedica generates no current revenue as a pre-commercial company, but plans to pursue regulatory approval through the FDA and other authorities, with the strategy of licensing or partnering its technology with larger pharmaceutical companies for development and commercialization.